Introduction

Product Candidates

Merus develops innovative Biclonics® (full length human IgG antibodies) designed to “close in on cancer” and improve lives of those afflicted. Our strategy employs our proprietary bispecific antibodies, their unique attributes and our patented screening technologies to engage and harness the power of the immune system to kill tumor cells.

Pipeline
Our pipeline comprises Biclonics® for solid and hematological tumors.

Merus' Laboratory

Programs

Pipeline

MCLA-128

  • Program
  • IND
  • Phase 1
  • Phase 2
  • Phase 3
Target: HER2, HER3
Breast Cancer

MCLA-128 is an antibody-dependent cell-mediated cytotoxicity (ADCC)-enhanced Biclonics® that targets the HER3 pathway. The bispecific antibody docks on HER2, abundantly expressed on tumor cells, and subsequently efficiently blocks heregulin-stimulated growth of tumor cells by binding to HER3. MCLA-128 is designed to overcome the inherent and acquired resistance of tumor cells to HER2-targeted therapies using two mechanisms: 1) blocking growth and survival pathways to stop tumor expansion and 2) recruitment and enhancement of immune effector cells to eliminate the tumor. MCLA-128 is being evaluated in a Phase 2 combination trial in two metastatic breast cancer populations. In HER2+ breast cancer, MCLA-128 will be combined with Herceptin plus or minus chemotherapy whereas in ER+/HER2low breast cancer, MCLA-128 will be combined with hormone therapy. Part 2 of the trial in the patient cohorts with metastatic ovarian, endometrium, gastric and lung cancer is ongoing. MCLA-128 has shown activity as a monotherapy in part 1 of a Phase 1/2 clinical trial which is being conducted in Europe. In addition, the Biclonics® was found to be safe and well-tolerated. The results from part 1 of the study lead to the expansion into several cohorts in part 2, including patients with, ovarian, endometrium, gastric and lung cancer. Merus expects to formulate its clinical development plans based on data readout from the ongoing Phase 1/2 monotherapy clinical trial in the second quarter of 2018.

Target: HER2, HER3
Gastric, Ovarian, Endometrial, NSCLC

MCLA-128 is currently being evaluated as a monotherapy in patients with metastatic ovarian, endometrium, gastric and lung cancer.

MCLA-117

  • Program
  • IND
  • Phase 1
  • Phase 2
  • Phase 3
Target: CD3, CLEC12A
Acute Myeloid Leukemia

MCLA-117 is a Biclonics® that binds to CD3, a cell-surface molecule present on all T cells, and CLEC12A, a cell surface molecule present on Acute Myleoid Leukemia (AML) cells and stem cells. MCLA-117 is designed to recruit and activate T-cells to kill CLEC12A-expressing AML tumor cells and stem cells, which may prevent recurrence of the tumor.

MCLA-158

  • Program
  • IND
  • Phase 1
  • Phase 2
  • Phase 3
Target: Lgr5, EGFR
Various solid tumors

MCLA-158 is an ADCC (Antibody-dependent cell-mediated cytotoxicity) -enhanced Biclonics® for the treatment of solid tumors, including the potential treatment of colorectal cancer, that binds to cancer stem cells expressing leucine-rich repeat-containing G protein-coupled receptor 5 and epidermal growth factor receptors. MCLA-158 is designed to use two different mechanisms of action. The first blocks growth and survival pathways in cancer stem cells. The second involves the recruitment and enhancement of immune effector cells to directly kill cancer stem cells that persist in solid tumors and cause relapse and metastasis.

MCLA-145

  • Program
  • IND
  • Phase 1
  • Phase 2
  • Phase 3
Target: PD-L1, undisclosed
Various solid tumors

MCLA-145 is a Biclonics® that is designed to positively modulate anti-tumor immunity. MCLA-145 binds PD-L1 with one arm and a second undisclosed target with the second arm. MCLA-145 simultaneously reverse immune system suppression at the tumor site while attracting immune effector cells to directly kill the targeted tumor.

This information reflects public disclosures current as of January 26, 2018. Merus’ product candidates pipeline will change over time as molecules move through the drug development process, including potentially progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Merus’ most recent Form 20-F and in Merus’ other periodic reports filed with the SEC, and actual results may vary materially. Merus provides this information as of the date above and does not undertake any obligation to update any forward-looking statements contained on these tables as a result of new information, future events or otherwise.

The new face of fighting cancer

Publications

Scientific publications

For an overview of all publications, please visit the publications overview page.

All publications
September 26, 2016
Immuno-Modulatory Receptor poster (September 2016)
Poster presentation, presented at CRI, CIMT, EATI and AACR meeting, September, 2016.
November 9, 2016
MCLA-117 SITC Poster (November 2016)
Poster presentation, presented at the Society for Immunotherapy of Cancer (SITC), Annual Meeting, November, 2016; National HArbour, Maryland, USA.
April 1, 2017
MCLA-158 AACR Poster (April 217)
Poster presentation, presented at the American Association for Cancer Research, Annual Meeting, April 1-5, 2017; Washington D.C., USA.
April 1, 2017
MCLA-128 AACR Poster (April 2017)
Poster presentation, presented at the American Association for Cancer Research, Annual Meeting, April 1-5, 2017; Washington D.C., USA.
June 2, 2017
MCLA-128 ASCO Poster (June 2017)
Poster presentation, presented at the American Society of Clinical Oncology, Annual Meeting, June 2-6, 2017; Chilago, Illinois, USA.
June 15, 2017
Biopharma Dealmakers – Merus Profile
Published article "Battling Cancer with Bispecific Antibodies" in BioPharma Dealmakers, June 2017.